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Abstract
Prolonged ER stress has been known to be one of the major drivers of impaired 
lipid homeostasis during the pathogenesis of non-alcoholic liver disease (NAFLD). 
However, the downstream mediators of ER stress pathway in promoting lipid ac-
cumulation remain poorly understood. Here, we present data showing the b-ZIP 
transcription factor E4BP4 in both the hepatocytes and the mouse liver is potently in-
duced by the chemical ER stress inducer tunicamycin or by high-fat, low-methionine, 
and choline-deficient (HFLMCD) diet. We showed that such an induction is partially 
dependent on CHOP, a known mediator of ER stress and requires the E-box element 
of the E4bp4 promoter. Tunicamycin promotes the lipid droplet formation and alters 
lipid metabolic gene expression in primary mouse hepatocytes from E4bp4flox/flox 
but not E4bp4 liver-specific KO (E4bp4-LKO) mice. Compared with E4bp4flox/flox 
mice, E4bp4-LKO female mice exhibit reduced liver lipid accumulation and partially 
improved liver function after 10-week HFLMCD diet feeding. Mechanistically, we 
observed elevated AMPK activity and the AMPKβ1 abundance in the liver of E4bp4-
LKO mice. We have evidence supporting that E4BP4 may suppress the AMPK activ-
ity via promoting the AMPKβ1 ubiquitination and degradation. Furthermore, acute 
depletion of the Ampkβ1 subunit restores lipid droplet formation in E4bp4-LKO pri-
mary mouse hepatocytes. Our study highlighted hepatic E4BP4 as a key factor link-
ing ER stress and lipid accumulation in the liver. Targeting E4BP4 in the liver may 
be a novel therapeutic avenue for treating NAFLD.
[Correction added on September 7, 2020, after first online publication: Figures 6 has been replaced with revised figure.]
13534 |   YANG et Al.
1 |  INTRODUCTION
The ER system is an intracellular organelle responsible for the 
folding of membrane-bound and secreted proteins, lipid and 
sterol synthesis, and calcium storage in eukaryotes.1,2 When un-
folded or misfolded proteins accumulate inside that ER lumen, 
ER stress triggers a group of signal transduction pathways 
namely “unfolded protein response (UPR)” to reprogram the 
transcriptional and translational processes for recovery or ad-
aptation. A variety of pharmacological agents and dietary ma-
nipulations have been shown to cause ER stress and interrupt 
the normal ER function.3,4 One of the metabolic consequences 
of ER stress in hepatocytes is lipid accumulation in the liver. 
Acute injection of the ER stress inducer tunicamycin in mice 
was shown to not only induce the UPR genes but also cause 
marked lipid droplet accumulation along with increased de 
novo lipogenesis and reduced fatty acid oxidation in the liver.5 
Methionine and choline deficient (MCD) diet, which is known 
to induce liver steatosis and injury, induces potent ER stress in 
the liver.6 These findings highlighted that ER stress might be a 
critical regulator of hepatic lipid accumulation, the early hall-
mark of non-alcoholic fatty liver disease (NAFLD).
The precise mechanisms of NAFLD remain poorly un-
derstood. Currently, the “multiple-hit hypothesis” has been 
recognized to address the development and progression of 
NAFLD.7,8 The initial hit leads to simple liver steatosis, 
while oxidative stress, insulin resistance, impairment in lipid 
metabolism, and Kupffer cell activation result in hepatic in-
flammation and apoptosis, prompting the progression from 
simple steatosis to non-alcoholic steatohepatitis (NASH).9 
Hepatocytes are rich in ER due to a high capacity for han-
dling protein and lipid biosynthesis. It has been hypothesized 
that impaired ER homeostasis may be directly involved in the 
onset and progression of NAFLD.2,10 For example, the mark-
ers of ER stress were elevated in the liver of NAFLD.6,11,12 
Chemical chaperons have been shown to not only reduce ER 
stress but also improve liver function.13,14 Deletion of the 
ER stress responsive chaperon p58IPK protects mice from 
diet-induced steatohepatitis.15 Several drugs including FXR 
agonists and GLP analogs have shown great promise in treat-
ing NAFLD/NASH through potent inhibition of the ER stress 
pathways in the liver.16,17
There has been an intense interest in the role of transcrip-
tion factors in the pathogenesis of NASH, particularly the ER-
stress associated transcription factors, such as CHOP, ATF4, 
XBP1, CREBH, and C/EBP-β.8 The Friedman group showed 
that deletion of C/ebp-β attenuates inflammation and lipid 
accumulation in diet-induced NASH.18 In contrast, Chop 
deletion results in more severe NASH following diet high in 
fat, fructose, and cholesterol.18,19 Hepatic Xbp1 deficiency 
sensitizes mice to diet-induced NASH.20 Crebh deficiency 
also accelerated the development of NAFLD in mice fed ath-
erogenic diet.21 These paradoxical results demonstrated the 
diverse functions of ER stress-associated transcription factors 
in the pathogenesis of NAFLD. Thus, a better understanding 
of the specific roles for individual components of the ER 
stress pathway may lead to effective treatment for NAFLD.
As a b-ZIP transcription factor, E4BP4 is ubiquitously ex-
pressed in various tissues, particularly abundant in the liver, 
spleen, and adipose tissue.22 Although E4BP4 is well-known 
for its critical role in NK cell development and lympho-
cytes23,24 and has been recently implicated in hepatic gluco-
neogenesis and the regulation of body composition,25,26 the 
involvement of E4BP4 in lipid metabolism remains largely 
unexplored. We previously reported that potent induction 
of E4BP4 by insulin contributes to the postprandial de novo 
lipogenesis in an SREBP-1c-dependent manner.27 E4bp4-
deficient hepatocytes exhibit a significant reduction in de 
novo lipogenesis, triglyceride content as well as the expres-
sion of lipogenic enzymes including Fasn and Scd1. The 
work from the Zhang group shows that E4BP4 could impact 
hepatic lipid metabolism via its interaction with CREBH, 
a liver-enriched ER-tethered transcription factor known to 
regulate hepatic lipid homeostasis.21 All these findings sup-
port a physiological role of E4BP4 in regulating hepatic 
lipid metabolism. Because dysregulated lipid metabolism is 
a major contributor to the pathogenesis of NAFLD, we set 
out to study the role of E4BP4 in this process. In the pres-
ent study, we report that E4BP4 is highly induced by either 
chemical or diet inducers of ER stress in hepatocytes and the 
liver. E4bp4-deficient hepatocytes are resistant to tunicamy-
cin-induced lipid accumulation. Moreover, the liver from 
E4bp4-LKO mice on NASH-inducing HFLMCD diet show 
decreased lipid accumulation, improved lipid metabolism, 
and reduced liver injury along with the enhanced AMPK sig-
naling. Our data demonstrated that hepatic E4BP4 may drive 
the pathogenesis of diet-induced NAFLD likely through its 
inhibitory effects on the AMPK pathway.
2 |  MATERIALS AND METHODS
2.1 | Animal and treatment
Animal experiments were conducted in accordance with 
the guidelines of the institutional Animal Care and Use 
K E Y W O R D S
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Committee of University of Michigan Medical School. Male 
C57BL/6J mice and Albumin-Cre mice were purchased from 
the Jackson Laboratory. E4bp4flox/flox mice were generated 
via the conventional homologous recombination targeting 
exon 2 of the trimouse E4bp4 at Cyagen (Santa Clara, CA). 
Liver-specific E4bp4 knockout (E4bp4-LKO) mice were 
generated by crossing E4bp4flox/flox mice with Albumin-Cre 
mice. All mice were housed on a 12  hours:12  hours light/
dark cycle at 25°C with free access to water and regular chow 
(26.8% kcal from protein, 16.6% from fat, and 56.4% from 
starch). At the age of 2  months, E4bp4 flox/flox and E4bp4-
LKO female mice were fed high-fat, low-methionine, and 
choline-deficient (HFLMCD: 45% calories from fat, 0.1% 
methionine, and choline-deficient) diet for 10  weeks. For 
Ampk-β1 knockdown experiment, 2-months-old WT mice 
were fed HFLMCD diet for 2 weeks, and then, injected with 
adenoviral shRNA against LacZ, E4bp4, or E4bp4 plus Ampk 
β1 through tail vein. After injection, mice continued with 
HFLMCD diet for another 10 days prior to liver harvesting 
for metabolic assays.
2.2 | Cell cultures
Hepa1c1c-7 cell was purchased from the ATCC and main-
tained according to the instructions. Isolation of primary 
mouse hepatocytes (PMHs) was described previously.27 
PMHs and Hepa1 cells were treated with DMSO and 5 μM 
tunicamycin for 24 hours and harvested for western blotting, 
RT-qPCR, and BODIPY staining.
2.3 | Liver Histology and  
Sirius-Red staining
Liver tissues were immediately fixed in 10% formalin at 
room temperature overnight after paraffin embedding and 
H&E staining. While the H&E-stained slides were observed 
directly under microscope, the unstained slides were baked 
in an oven set at 58ºC for 1 hour. And the paraffin sections 
were rehydrated in ethanol solutions in various concentra-
tions. Then, the slides were stained with Picro-Sirius Red 
Collagen Stain Kit (Sigma, Direct Red 80, 365548; FAST 
Green, 7252) or Masson's Trichrome Stain Kit (Sigma, 
HT15-1KT) according to the user's manuals and observed 
under microscope.
2.4 | Transfection and luciferase assay
A total of 2 x 105 293AD cells were seeded in 24-well 
plates. Transfection was performed with Opti-MEM (Gibco, 
2021431) and polyethylenimine (PEI). The β-gal expression 
plasmid and Chop-HA over-expression plasmids were co-
transfected with the E4bp4 WT promoter or the E4bp4 ΔE-
box promoter-driven luciferase reporter construct plus the 
β-gal expression plasmid. Twenty-four hours later, the cells 
were harvested for luciferase and β-gal assays. Luciferase 
assay was performed with Luciferin (Gold Biotechnology, 
103404-75-7) and normalized by the β-gal signal.
2.5 | Protein extraction and 
immunoprecipitation
To prepare cytosolic and nuclear proteins, liver tissues were 
homogenized in hypotonic buffer, incubated on ice for 
15-20 minutes, and centrifuged at 3000 rpm for 10 minutes 
at 4°C. The supernatant was saved as the cytosolic fraction. 
The pellet was washed once with hypotonic buffer and re-
suspended in RIPA buffer prior to sonication for 5 seconds. 
The nuclear fraction was then collected after centrifugation at 
13 000 × rpm for 10 minutes. Western blot analysis was per-
formed using the following primary antibodies: anti-GAPDH 
(Santa Cruz, sc-25778), anti-Lamin A/C (Santa Cruz, sc-
20681), anti-HSP90 (Santa Cruz, sc-13119), anti-CHOP 
(Santa Cruz, sc-575), anti-GRP78 (Santa Cruz, sc-13968), 
anti-E4BP4 (Santa Cruz, sc-28203; Cell Signaling, 14312S; 
DSHB, PCRP-NFIL3-2B5), anti-AMPK-pT172 (Cell Signaling, 
2531S), anti-AMPK α1/α2 (Cell Signaling, 5831S), anti- 
AMPK-β1 (Santa Cruz, sc-100357), anti-AMPK-γ1 (Santa 
Cruz, sc-19138), anti-β-tubulin(Sigma,T5201), and anti-FLAG 
(Sigma, A8592).
2.6 | cDNA Synthesis and qPCR
Total cellular RNA extraction was performed with TRIzol 
(Invitrogen) and chloroform. cDNA was synthesized with the 
Verso cDNA kit (Thermo Fisher Scientific) and subjected to 
qPCR analysis with Radiant Green 2X qPCR Mix (Alkali 
Scientific) on an ABI 7900 HT thermal cycler (Applied 
Biosystems). The value of each cDNA was calculated using 
the ΔΔCT method and normalized to the values of the house-
keeping gene control, the 18s ribosomal RNA. The data were 
plotted as fold change. The primer sequences are listed below 
(Table 1).
2.7 | BODIPY staining
Primary mouse hepatocytes (PMHs) were isolated from 
E4bp4 flox/flox and E4bp4-LKO mice using a previously re-
ported protocol. A total of 8 × 104 cells were seeded per well 
of 12-well plates. Next day, cell culture medium was changed 
to serum-free DMEM (Gibco) and the cells were treated with 
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DMSO or tunicamycin (5 μg/mL). Twenty-four hrs later, the 
cells were stained with BODIPY (Invitrogen, D3922, 493/503, 
2 μM) using a protocol described by Bo Qiu.33
2.8 | Plasma and liver metabolite 
measurements
Serum cholesterol, triglycerides (TG), and alanine transami-
nase (ALT) were measured using the commercial kits (Pointe 
Scientific A7510, A7525, and T7532) according to the manu-
facturer's instructions. For liver TG content, liver tissues were 
homogenized for total lipid extraction according to Bligh and 
Dyer (Bligh and Dyer 1959). Total lipids were re-suspended 
in 400 μL of 100% ethanol. A total of 3 μL were used for 
the measurement of TG with the TG kit (Pointe Scientific 
T7532).
2.9 | Statistical analysis
All data are reported as Mean  ±  SD Differences between 
two groups were assessed by the two-tailed Student's t test. 
Difference between more than two groups was analyzed by 
ANOVA followed by the Tukey's post hoc testing. P value 
< .05 was deemed statistically different.
3 |  RESULTS
3.1 | E4BP4 is a novel target induced by ER 
stress in hepatocytes
We previously reported that insulin induces the E4bp4 
expression via an SREBP-1c-dependent manner and such 
an induction is critical for de novo lipogenesis in hepato-
cytes.27 Whether the E4bp4 expression is also sensitive to 
other lipogenic stimuli remains unknown. A recent study re-
ported that the ER stress inducer tunicamycin increases the 
E4bp4 expression in pancreatic β-cells and impairs β-cell 
metabolism and insulin secretion.29 Given the sensitivity of 
hepatocytes to ER stress stimuli, we tested whether tunica-
mycin could induce E4bp4 by treating both PMHs for indi-
cated time points. Induction of the Chop mRNA confirmed 
the positive response to tunicamycin stimulation in hepato-
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as 2 hours following tunicamycin treatment and peaked at 
4 hours with an increase by threefold (Figure 1A). Since the 
saturated fatty acid palmitate was shown to trigger ER stress 
in hepatocytes,30 we treated hepatocytes with palmitate and 
observed a similar elevation of E4bp4 expression in PMHs 
(Figure  1B). In contrast, oleic acid (OA), an unsaturated 
fatty acid, showed no effect on the expression of either 
Chop or E4bp4 mRNA in mouse hepatocytes (Figure 1C). 
Lastly, we observed a time-dependent induction of E4BP4 
protein in PMHs (Figure  1D). Of note, similar results 
were observed in the mouse hepatoma Hepa1c1c7 cell line 
(Figure S1A-D).
To test whether this response is also conserved in the 
mouse liver, we challenged WT mice with tunicamycin 
through intraperitoneal injection. Eight and 24 hours post in-
jection, we examined both the protein and mRNA expression 
of E4bp4 in the liver. Indeed, liver E4bp4 mRNA and protein 
were potently induced by tunicamycin injection along with 
the induction of GRP78 (Figure 1E,F), a well-known target 
of acute ER stress response. Collectively, these data support 
that E4BP4 is a novel target of the ER stress responses in both 
hepatocytes and the liver.
Interestingly, E4BP4 induction as a novel target of the 
ER stress response is not limited to only hepatocytes. We 
also detected the elevated levels of both E4bp4 mRNA and 
protein after tunicamycin treatment in the mouse macrophage 
RAW264.7 cells (Figure S2A,B).
3.2 | HFLMCD diet feeding increases liver 
E4BP4 expression in WT mice
A variety of diets enriched in saturated fat and cholesterol 
with certain nutrient depletion have been used to induce he-
patic ER stress.6,11 In particular, high-fat, low methionine, 
and choline-deficient (HFLMCD) diet has been shown to 
stimulate hepatocyte ER stress, liver steatosis, and liver in-
flammation in a relatively short duration.31 In our hands, 
feeding with HFLMCD diet for 10 weeks led to elevated lev-
els of serum ALT, liver TG, and liver cholesterol (Figure 2A-
C), while liver histology demonstrated clear signs of lipid 
accumulation by H&E staining and fibrosis by Sirius Red 
staining (Figure  2D), mimicking human NASH. We also 
detected a significant induction of hepatic E4bp4 mRNA of 
female mice and a remarkable increase of hepatic E4BP4 pro-
tein in male mice along with the elevated ER stress marker 
Chop mRNA after 10-week HFLMCD diet (Figure 2E,F and 
Figure S2C,D). Taken altogether, our data for the first time 
demonstrate that hepatic E4BP4 is elevated in the liver of 
mice with HFLMCD diet-induced steatosis and fibrosis.
F I G U R E  1  ER stress induces E4bp4 mRNA and protein in primary hepatocytes and mouse liver. A-C, Primary mouse hepatocytes were 
isolated from WT mice and then, treated with tunicamycin at 5 μg/mL for 2, 4, and 8 hours (A), or palmitate (400 μM) (B) or oleic acid (300 μM) 
(C) for 24 hours before harvest for mRNA analysis. The mRNA levels of Chop and E4bp4 were examined by RT-qPCR. D, The protein levels of 
E4BP4 in primary hepatocytes were determined by immunblotting during a time-course study of tunicamycin treatment (E-F) WT male mice were 
acutely injected with either DMSO (n = 3-7) or tunicamycin (n = 3-6) and liver tissues were harvested at either 8 or 24 hours for both mRNA and 
protein analysis. The mRNA abundance of Grp78, E4bp4, and Ppar-γ was analyzed by RT-qPCR, whereas the protein levels of E4BP4 and GRP78 
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3.3 | CHOP is partially required for 
tunicamycin-induced E4bp4 expression
The transcriptional program upon ER stress has been well 
characterized in mammalian cells.1 CHOP acts downstream 
of the PERK-ATF4 pathway to promote cell death during 
prolonged ER stress.32 Hepatic induction of CHOP follow-
ing tunicamycin injection is necessary for the suppression 
of genes critical for lipid metabolism.33 Interestingly, the 
global Chop KO mice fed a diet high in fat, fructose, and 
cholesterol for 16 wks developed more severe histologi-
cal features of NASH compared with WT controls.19 We, 
therefore, examined whether Chop knockdown affects the 
tunicamycin-induced E4bp4 in both cultured hepatocytes 
and the mouse liver. Acute depletion of Chop in hepato-
cytes was achieved by transduction with Ad-shChop and 
confirmed by RT-qPCR (Figure 3A). In PMHs, tunicamy-
cin induced a robust increase of E4bp4, Chop, and Grop78 
in Ad-shLacZ-transduced controls, whereas Chop deple-
tion largely abrogated the E4bp4 induction without affect-
ing Grp78 (Figure 3A). A similar loss of E4bp4 induction 
was observed in the Ad-shChop-injected mouse liver after 
tunicamycin injection (Figure 3B), suggesting that CHOP 
is required for the maximal E4bp4 induction by tunicamy-
cin in hepatocytes and the liver.
Given the role of CHOP as a transcription factor, we 
hypothesized that CHOP could directly activate the pro-
moter of E4bp4 in response to tunicamycin. We did find 
that the ectopic expression of HA-Chop induced the lucifer-
ase activity driven by the mouse E4bp4 promoter in a dose- 
dependent manner in 293A cells (Figure 3C). We previously 
reported that the E-box element within the proximal region 
of the E4bp4 promoter is important for its activation by 
SREBP-1c.27 Thus, we tested whether this response element 
is also required for the CHOP-mediated induction by gen-
erating a mutant reporter construct with the deletion of the 
E-box element. As shown in Figure 3D, Chop overexpres-
sion was only able to activate the E4bp4- WT-luc but not 
the E4pb4-ΔE-box-luc mutant, suggesting that this E-box 
element is indeed critical for the transcriptional activation 
of E4bp4 by CHOP (Figure 3D). However, we were unable 
to detect direct binding of CHOP to the E4bp4 promoter by 
ChIP assay (data not shown), indicating that CHOP might 
stimulate other transcription factors to activate the E4bp4 
promoter.
F I G U R E  2  HFLMCD diet induces E4BP4 expression in the mouse liver. C57BL6 female mice were fed either regular chow (n = 4) or 
HFLMCD diet (n = 8) for 10 wks to induce NASH prior to the following assays: A, serum ALT; B-C, total liver TG & cholesterol; D, liver 
histology by H&E staining and liver fibrosis by Sirius Red staining; E and F, Liver E4bp4 mRNA and protein expression in regular chow vs 
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3.4 | E4BP4 is required for tunicamycin-
induced lipid droplet accumulation in cultured 
hepatocytes
Both acute and chronic ER stress potently impact hepatic 
lipid homeostasis.10 For example, administration of tunica-
mycin into WT mice was reported to influence lipid synthe-
sis and breakdown, leading to massive liver steatosis.5 We 
previously reported that E4BP4 mediates de novo lipogen-
esis downstream of the insulin signaling in hepatocytes.27 To 
test whether E4BP4 is involved in the tunicamycin-induced 
lipid accumulation in hepatocytes and the liver, we generated 
E4bp4 liver-specific knockout (E4bp4-LKO) mice by cross-
ing E4bp4flox/flox mice with Alb-Cre transgenic mice and vali-
dated the liver-specific deletion of E4BP4 (Figure 4A). Next, 
we challenged both E4bp4flox/flox and E4bp4-LKO PMHs with 
tunicamycin, and analyzed the impact of E4bp4 deficiency 
on lipid droplet formation and TG content in hepatocytes. 
As shown by BODIPY staining,28 overnight incubation of 
tunicamycin markedly increased both the number and size 
of lipid droplets in E4bp4flox/flox hepatocytes. However, 
tunicamycin-induced lipid droplets were nearly abolished 
in the E4bp4-LKO PMHs (Figure  4B), consistent with the 
reduced levels of TG content in tunicamycin-treated E4bp4-
LKO vs E4bp4flox/flox PMHs (Figure 4C). These observations 
support that E4BP4 is indeed required for lipid droplet ac-
cumulation in response to tunicamycin-induced ER stress in 
hepatocytes.
Lipid homeostasis in hepatocytes is a dynamic process 
coordinated via lipid uptake, lipid synthesis, fatty acid ox-
idation, and lipid export.34 To explore the downstream tar-
gets of E4BP4 during lipid accumulation in hepatocytes, 
we measured the mRNA expression of common lipid met-
abolic pathways in PMHs. On the one hand, tunicamycin 
elevated the expression of Fasn while repressing Cpt1a in 
E4bp4flox/flox but not E4bp4-LKO PMHs (Figure  4D). On 
the other hand, there were no differences in the expression 
of genes involved in autophagy, lipolysis, and lipid export 
between those two groups (Figure S3). Chronic ER stress 
also has been reported to induce hepatocyte apoptosis.35,36 
We, therefore, examined whether E4BP4 is required for this 
process. As shown in Figure  S5, tumicamycin treatment 
F I G U R E  3  Chop is critical for the induction of E4bp4 by tunicamycin in PMHs and the mouse liver. A, PMHs were transduced with 
AdshlacZ or Ad-shChop before treatment of tunicamycin for 24 hours. The cells were then harvested for mRNA analysis of E4bp4, Chop, and 
Grp78. B-C, WT mice were tail-vein injected with either AdshLacZ or AdshChop for 10 days before intra-peritoneal injection of DMSO or 
tunicamycin for 24 hours. The mRNA and protein levels of E4BP4 were analyzed by TR-qPCR and immunoblotting, respectively. C, Activation 
of the E4bp4 promoter activity by ectopic expression of Chop. 293AD cells were transfected with a luciferase reporter construct driven by the 
E4bp4-WT promoter plus an increasing amount of the HA-Chop expression construct. The luciferase activity was normalized by the β-gal activity. 
D, The E-box element in the promoter is required for its induction by CHOP. A total of 293AD cells were transfected with the E4bp4-WT-luc or 
the E4bp4-ΔE-box-luc mutant plus the HA-Chop expression construct. The luciferase activity was normalized by the β-gal activity. Data were 
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F I G U R E  4  Hepatic E4bp4 is required for tunicamycin-induced accumulation of lipid droplets in PMHs. A, Validation of liver-specific 
E4bp4 deficiency in various tissues isolated from both E4bp4flox/flox (n = 3) and E4bp4-LKO (n = 3) mice by RT-qPCR. PMHs were isolated from 
E4bp4flox/flox and E4bp4-LKO mice and treated with tunicamycin overnight prior to BODIPY staining for lipid droplets and RNA extraction for  
RT-qPCR. B, Image of lipid droplet formation after tunicamycin treatment; lipid droplets in 50 cells were countered per condition and presented in 
the bar graph. C, Cellular triglycerides (TG) content in tunicamycin-treated E4bp4flox/flox or E4bp4-LKO PMHs. D, Lipid metabolic genes assessed 




F I G U R E  5  Loss of hepatic E4bp4 protects mice from HFLMCD diet-induced lipid accumulation in the liver. Both E4bp4 flox/flox and E4bp4-
LKO were fed HFLMCD diet for 10 weeks before sacrifice for the following assays: A and B, body weight and liver weight/body weight ratio; 
C, serum ALT, TG, and cholesterol; D, liver TG and cholesterol; E, Liver histology by H&E staining; F, Quantification of lipid metabolic gene 
expression in the liver. G, Immuoblotting of AKT-PS473, ATK, lipogenic enzymes, and SREBP-1c in the liver. *P < .05; **P < .01, compared with 
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significantly induced pro-apoptotic genes including Noxa 
and Puma in E4bp4flox/flox but not E4bp4-LKO PMHs, 
indicating that E4BP4 induction may contribute to ER 
stress-induced apoptosis. Together, these findings reveal a 
broad role of E4BP4 in lipid metabolism and hepatocyte 
apoptosis following ER stress.
3.5 | Loss of hepatic E4bp4 protects against 
HFLMCD diet-induced lipid accumulation
Given the important role of ER stress in hepatocytes dur-
ing NAFLD2 and the elevated E4BP4 expression in the 
liver of the HFLMCD diet-induced ER stress mouse model 
(Figure 2), it was logical to examine whether manipulation 
of hepatic E4BP4 impacts lipid metabolism and NAFLD in 
vivo. We first compared E4bp4flox/flox vs E4bp4-LKO mice 
on regular chow following fasting overnight and refeeding 
for 12 hours. The reason we chose to refeed mice is because 
the E4BP4 mRNA and protein tend to be potently induced 
by refeeding.37 Body weight, TG, and cholesterol in serum/
liver, as well as serum ALT all turned out to be comparable 
between the two groups of mice (Figure S6), supporting that 
hepatic E4BP4 is dispensable in liver lipid metabolism under 
the normal physiological condition.
Next, we examined the impact of hepatic deletion of 
E4bp4 on lipid metabolism following HFLMCD diet. Upon 
10-wk HFLMCD feeding, both E4bp4flox/flox and E4bp4-
LKO mice showed similar body weight gain (Figure 5A). 
However, the ratio of liver weight/body weight was sig-
nificantly reduced in E4bp4-LKO mice (Figure 5B). Serum 
ALT, the classical marker for liver injury, was about 20% 
lower in E4bp4-LKO mice (Figure  5C). Despite compa-
rable levels of serum TG and cholesterol in both groups 
of mice (Figure  5D), E4bp4-LKO mice accumulated sig-
nificantly less TG, total cholesterol, and lipid droplets in 
the liver by H&E staining (Figure 5D,E). In summary, all 
these data suggest that E4bp4-LKO mice are protected 
from HFLMCD-induced liver steatosis and cholesterol 
accumulation.
To further explore how E4bp4 deficiency renders mice re-
sistant to liver steatosis, we measured the genes of major lipid 
metabolic pathways in both groups of mice. In comparison 
with E4bp4flox/flox mice, E4bp4-LKO mice showed signifi-
cantly lower expression of genes involved in de novo lipo-
genesis (Acc1 and Scd1) and lipid droplet formation (Plin4) 
in the liver (Figure 5F). At the protein levels, SCD1 protein 
levels were markedly reduced in the liver of E4bp4-LKO 
mice (Figure 5G). Of note, liver-specific Scd1 knockout mice 
showed less lipid accumulation in the liver in response to 
high-carbohydrate diet.38,39 In contrast, no significant differ-
ences were detected in the genes involved in lipolysis, choles-
terol biosynthesis, fatty acid oxidation, and fatty acid uptake 
in the liver between those two groups of HFLMCD diet-fed 
mice (Figure S7).
Since NASH is associated with increased liver inflamma-
tion and fibrosis, we then compared the expression of inflam-
matory and fibrotic markers in the liver between E4bp4flox/flox 
and E4bp4-LKO mice following HFLMCD. The mRNA lev-
els of inflammatory cytokines (Tnfα, Il-1β, Mcp1, and F4-80) 
as well as fibrotic genes (Cola1, αSma, and Tgfβ) in the liver 
were comparable between the two groups (Figure S8A,B), in 
agreement with the similar staining pattern of the liver tis-
sues by Masson's Trichrome staining (Figure  S8C). These 
data suggest that under the diet-induced ER stress condition, 
hepatic E4bp4 deficiency protects mice from lipid accumula-
tion without impacting inflammation and fibrosis in the liver.
3.6 | The role of AMPK suppression 
in E4BP4-driven lipid accumulation in 
hepatocytes
To further uncover the molecular mechanisms underlying 
the reduced expression of de novo genes and lipid accumula-
tion in the liver of HFLMCD diet-fed E4bp4-LKO mice, we 
focused on the energy-sensing kinase AMPK, a critical reg-
ulator of lipid homeostasis in the liver.40 It has been well rec-
ognized that the AMPK-dependent phosphorylation of ACC 
potently inhibits de novo lipogenesis in the liver,41 whereas 
the AMPK-dependent phosphorylation of ATGL promotes 
lipolysis.42 Several in vivo studies revealed the beneficial 
effects of chronic AMPK activation on diet-induced liver 
steatosis.43,44 Whether hepatic E4bp4 deficiency could affect 
the AMPK pathway in hepatocytes and subsequently diet-
induced lipid accumulation in the liver is currently unknown.
AMPK activation is marked by AMPK phosphoryla-
tion at T172.45 We first examined the effect of E4bp4 de-
ficiency on AMPK-PT172 in the liver of HFLMCD diet-fed 
mice. Indeed, the AMPK-PT172 levels were elevated in the 
liver of E4bp4-LKO mice following HFLMCD diet feed-
ing (Figure 6A). Similarly, we observed increased levels of 
AMPK-PT172 in E4bp4-LKO PMHs (Figure 6B), supporting 
that E4BP4 regulates AMPK-PT172 in a cell-autonomous 
manner in hepatocytes. Conversely, adenoviral over-expres-
sion of E4BP4 substantially reduced not only the basal but 
also the 2-Deoxy-D-glucose-induced AMPK-PT172 in WT 
mouse hepatocytes (Figure 6C). These findings collectively 
support that E4BP4 acts as a negative regulator of the AMPK 
pathway in hepatocytes.
To test how hepatic E4BP4 regulates the AMPK path-
way, we examined whether E4BP4, as a transcription fac-
tor, affects the expression of hepatic Ampk subunits. The 
mRNA levels of the major AMPK subunits were com-
parable in the liver of E4bp4flox/flox vs E4bp4-LKO mice 
(Figure S9A). However, at the protein level, AMPKβ1 was 
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markedly elevated in both E4bp4-LKO PMHs (Figure 6D) 
and the liver of E4bp4-LKO mice (Figure  S9B). These 
data suggest that E4BP4 might control the proteolysis of 
AMPKβ1 in hepatocytes.
AMPKβ1 is the scaffolding subunit in the intact AMPK 
kinase complex in mouse hepatocytes.46 Interestingly, we 
found that, under the tunicamycin-induced ER stress, only 
the AMPKβ1 protein abundance was reduced (Figure S9D). 
To directly test the impact of E4BP4 on the AMPK-β1 deg-
radation, we measured the protein half-life of AMPKβ1 in 
Ad-E4bp4-transduced Hepa1 cells in cycloheximide chase 
analysis. In cells transduced with Ad-GFP, AMPKβ1 had a 
half-life of about 3 hours. However, its half-life was short-
ened to less than 2 hours in cells transduced with Ad-E4bp4 
(Figure  6E). This observation was consistent with the for-
mation of AMPKβ1-polyubiquitin conjugates in Ad-E4bp4-
transduced PMHs (Figure  S10A). We previously reported 
that E4BP4 forms a complex with the nuclear SREBP-1c 
and promotes lipogenic gene expression in response to in-
sulin signaling.27 We, therefore, checked whether SREBP-1c 
over-expression affects the AMPKβ1 protein abundance just 
like E4BP4. As shown in Figure S10B, adenoviral SREBP-1c 
overexpression showed no effect on the AMPKβ1 abundance 
in cultured hepatocytes, suggesting that the E4BP4 action 
on the AMPKβ1 stability is likely to be independent of 
SREBP-1c in hepatocytes.
How does E4BP4 controls the AMPKβ1 proteolysis? We 
speculate that E4BP4 may control the expression of critical 
regulators that either promote or suppress the stability of 
AMPKβ1 in hepatocytes. It has been reported that the ubiqui-
tin E3 ligase MKRN targets the AMPKα subunits for degrada-
tion, whereas the ubiquitin-specific protease USP10 protects 
the AMPK complex from proteolysis.47-49 We screened the 
expression of the reported regulators of the AMPK complex 
by RT-qPCR and found that several AMPK-specific E3 li-
gases including Rnf44, Ube2e, and, Celebron49-51 were sig-
nificantly downregulated in the liver of E4bp4-LKO mice 
following HFLMCD diet feeding (Figure  6F). Thus, it is 
likely that E4BP4 could suppress the AMPKβ1 protein sta-
bility via the upregulation of these E3 ligases.
Since AMPKβ1 is essential for the integrity of the 
AMPK protein complex,46 we reasoned that the depletion 
of Ampk-β1 by shRNA could lead to the disassociation of 
the AMPK kinase complex and subsequently suppress lipid 
F I G U R E  6  E4BP4 targets the AMPK-β1 subunit to mediate the tunicamycin-induced lipid accumulation in hepatocytes. A, Comparison of 
AMPK activation by anti AMPK-phosphorylation at T172 in the liver E4bp4flox/flox and E4bp4-LKO mice following HFLMCD feeding. B, The 
levels of AMPK-PT172 in PMHs from E4bp4flox/flox and E4bp4-LKO mice. C, Adenoviral over-expression of E4BP4 in WT PMHs reduces the 
basal and 2-Deoxy-D-glucose-induced AMPK-PT172 level. D, The protein abundance of AMPK subunits in E4bp4flox/flox and E4bp4-LKO PMHs 
by immunoblotting. D, Effect of E4BP4 overexpression on the stability of AMPK-β1. E, Effect of acute depletion of Ampk-β1 by adenoviral 
shAmpk-β1 on lipid droplets in E4bp4-LKO PMHs following tunicamycin treatment. The knockdown efficiency of Ad-shAmpk-1 was confirmed 
by immunblotting with anti-AMPK-β1. F, The mRNA levels of candidate ubiquitin E3 ligases in the liver of E4bp4flox/flox and E4bp4-LKO mice 
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droplet formation in E4bp4-LKO PMHs. To test this hypoth-
esis, we challenged E4bp4-LKO PMHs with tunicamycin 
after depleting Ampkβ1 with Ad-shAmpk-β1 (validated by 
immunoblotting in Figure  6G) and then, performed lipid 
droplet staining. As shown in Figure 6G, no increase of lipid 
droplets was detected in Ad-shLacZ-transduced E4bp4-LKO 
PMHs after tunicamycin treatment. However, knockdown of 
Ampk-β1 led to a drastic induction of lipid droplets in E4bp4-
LKO PMHs in the presence or absence of tunicamycin treat-
ment. In summary, our data support that E4BP4 is likely to 
target the AMPKβ1 subunit to promote lipid accumulation in 
hepatocytes in response to ER stress inducers.
4 |  DISCUSSION
Previously, we reported that the b-ZIP transcription factor 
E4BP4 could be induced in the liver via actions of nutri-
tional and hormonal signaling to regulate hepatic lipid me-
tabolism.22,27 Here we demonstrate that ER stress potently 
induces E4BP4 in the liver and hepatocytes to cause lipid ac-
cumulation in the liver. Depletion of hepatic E4bp4 not only 
protects against tunicamycin-induced lipid droplet accumula-
tion in cultured hepatocytes but also reduces liver steatosis 
in a diet-induced NAFLD mouse model. At the mechanistic 
level, we found that CHOP is required for the maximal in-
duction of E4BP4 by ER stress in hepatocytes. We discov-
ered that E4bp4 deletion impairs hepatic de novo lipogenesis 
and lipid accumulation likely through promoting the AMPK 
activity in hepatocytes following ER stress. Our findings 
point to E4BP4 as a novel target for treating liver diseases 
associated with ER stress (Figure S10C).
It has been established that ER stress promotes NAFLD 
by altering hepatic lipid metabolism.4,10 Specific effectors of 
ER stress pathway and their downstream signaling molecules 
have been examined in cell cultures and animal models for 
their roles in the ER stress-induced lipid accumulation in he-
patocytes. A PERK inhibitor was found to improve liver ste-
atosis and insulin sensitivity in an animal model of NAFLD.52 
In contrast, deletion of Ire1 leads to spontaneous liver steato-
sis,53 indicative of the unique functions of specific ER stress 
mediators in regulating lipid metabolism. In the current study, 
we obtained direct evidence from E4bp4-LKO PMHs to sup-
port the essential role of E4BP4 in tunicamycin-induced lipid 
accumulation in hepatocytes. A similar observation was also 
made in the liver of HFLMCD challenged E4bp4-LKO mice. 
To investigate the impact of hepatic E4bp4 deficiency with a 
stronger relevance to advanced human NAFLD in the future, 
we intend to feed E4bp4-LKO mice a diet rich in saturated 
fat, cholesterol, and sugars.54 Recently, the Koo group ob-
served reduced E4BP4 in the liver of either 27-week high-fat 
(60% calories from fat) diet-fed WT or ob/ob mice and pro-
vided evidence in support of E4BP4 as a negative regulator 
of hepatic gluconeogenic genes.25 In our study, both tunica-
mycin injection and 10-week HFLMCD (45% calories from 
fat) diet feeding potently induce the mRNA and protein levels 
of E4BP4 in the liver of E4bp4flox/flox mice. We speculate that 
genetic backgrounds, the type of nutritional stress, and feed-
ing regimen may all contribute to the differences between the 
studies, highlighting the complexities in the E4BP4-regulated 
metabolic responses in the liver.
In our study, we examined lipid metabolism genes to 
assess how E4BP4 impacts lipid metabolism following ER 
stress. Consistent with our previous studies,27 several de 
novo lipogenic genes including Fasn and Acc1 were reduced 
in the absence of E4bp4 in hepatocytes. However, E4bp4 
deficiency did not seem to impact fatty acid oxidation, lipid 
transport, and lipolysis gene expression. We speculated that 
hepatic E4bp4 deficiency might repress the activity of lipid 
metabolic enzymes via the AMPK pathway without signifi-
cantly affecting the mRNA levels of these lipid metabolic 
enzymes. Our data indeed show that inhibition of the AMPK 
pathway by acute knockdown of Ampk-β1 restores lipid drop-
let formation in E4bp4-LKO PMHs. AMPK is a master regu-
lator of multiple metabolic pathways and have been targeted 
in treating obesity, insulin resistance, type 2 diabetes, and 
NAFLD.40,55,56 One of our novel findings is that E4BP4 is 
both necessary and sufficient to inhibit the cellular AMPK 
activity in hepatocytes. E4bp4-deficiency in hepatocytes en-
hances the levels of AMPK-PT172, the hallmark of AMPK 
activation, whereas E4bp4 overexpression inhibits AMPK-
PT172. The Sternberg's group proposed three potential mech-
anisms by which AMPK activation may improve NAFLD: 
(1) the suppression of hepatic de novo lipogenesis; (2) the 
enhancement of fatty acid oxidation; and (3) the improve-
ment of the mitochondrial function/integrity in adipose tis-
sue.40,56,57 Surprisingly, despite the reduced ATP content in 
the livers of patients with NAFLD, hepatic AMPK activity 
was actually reduced, suggesting that AMPK activation could 
be regulated independently of ATP levels in the liver during 
NAFLD.56,58 Our data point out that E4BP4 could be a criti-
cal factor that links nutritional stress and AMPK suppression 
in hepatocytes during NAFLD. Therefore, the suppression of 
E4BP4 may be a valid avenue to activate hepatic AMPK ac-
tivity for the treatment of NAFLD.
So, how does E4BP4 suppress the AMPK signaling in 
the liver? There has been extensive research on how the 
intracellular ADP:ATP ratio activates AMPK.57 However, 
very little is known about how the changes of the major 
components of the AMPK complex affect its activity. We 
found that the mRNA abundance of Ampk subunits was sim-
ilar in the liver between E4bp4flox/flox and E4bp4-LKO mice 
(Figure S9A). In contrast, the protein level of the AMPKβ1 
subunit was elevated in both E4bp4-LKO PMHs and liver 
tissues. Moreover, E4BP4 overexpression enhances the 
ubiquitination of AMPKβ1 and accelerates the degradation 
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of the AMPKβ1 subunit in hepatocytes. Therefore, E4BP4 
is likely to inhibit hepatic AMPK pathway by enhancing 
the AMPKβ1 ubiquitination and degradation. So far, the 
AMPK subunits were shown to undergo the E3 ligase-me-
diated ubiquitination and degradation. A case in point, 
the lipid droplet-binding protein CIDEC was reported to 
interact with the AMPKα subunits and promote its ubiq-
uitination-dependent degradation during adipogenesis.59 
Recently, several E3 ligases were reported to modulate the 
protein stability of the AMPK complex, including MKRN, 
CRBN, RNF44, and UBE2O.47,49-51 MKRN1 was found to 
directly target the AMPK-α subunits for ubiquitination and 
degradation.47 MKRN-null mice showed chronic AMPK 
activation in both liver and adipose tissues and were pro-
tected against diet-induced metabolic dysfunction. RNF44 
promotes the degradation of AMPKα1 in melanoma cells 
in response to arginine deprivation.50 The E3 ligase CRBN 
binds to the AMPK complex and degrades the AMPKα 
subunits in multiple cell types.49 The Song group reported 
that UBE2O acts as a ubiquitin E3 ligase for the AMPK-α2 
subunit in skeletal muscles.49 Intriguingly, we found that 
the mRNA levels of RNF44, CRBN, and Ube2O but not 
MKRN were significantly reduced in the liver of E4bp4-
LKO mice. Our future study will determine whether these 
E3 ligases are involved in the regulation of the AMPKβ1 
stability downstream of E4BP4 induction in hepatocytes in 
response to chronic ER stress.
ER stress in macrophages is important for inflamma-
tion and the inflammasome activation. Interestingly, we 
observed that, in the RAW264.1 macrophage cell line, tu-
nicamycin also potently induces E4bp4 mRNA and protein 
expression (Figure  S2), suggesting that the ER stress-in-
duced E4BP4 pathway could be conserved in multiple cell 
types. It has been reported that the ER stress pathway is 
activated in Kupffer cells during NAFLD, resulting in the 
M1-type polarization of macrophages and subsequently 
increased liver injury.60 Even though the essential role of 
E4BP4 in NK cell development was widely reported,23 so 
far, the contribution of E4BP4 in ER-stressed macrophages 
to NAFLD remains unknown. We will explore the role of 
E4BP4 in Kupffer cells during the pathogenesis of NAFLD 
by generating a mouse model with the macrophage-specific 
deletion of E4bp4 for future study.
One important finding in our study is the gender-specific 
protection against HFLMCD-induced NASH. Only female 
E4bp4-LKO mice were protected from TG and cholesterol 
accumulation in the liver even although hepatic E4BP4 
was elevated in both female and male mice following 10-
week HFLMCD diet. It has been previously recognized that 
NAFLD is a sexually dimorphic disease and the metabolic 
impact of sex hormones is likely to account for the differ-
ences between genders.61 In a human study, over 1000 genes 
display a sex bias in their expression in the liver with the top 
biological pathways related to lipid metabolism.62 Currently, 
there are no data suggesting a crosstalk between E4BP4 and 
the estrogen signaling in the liver. For future study, we will 
identify the gender-specific downstream targets of E4BP4 
that might regulate lipid metabolism and the AMPK signal-
ing in a sexually dimorphic manner.
In summary, we have shown that both the E4bp4 mRNA 
and protein are highly inducible by ER stress signals in cul-
tured hepatocytes and the mouse liver. We also showed that 
hepatic E4BP4 is required for lipid accumulation in response 
to ER stress signals. E4bp4 liver-specific knockout mice are 
partially protected from hepatic lipid accumulation and in-
jury induced by HFLMCD diet, likely due to the enhanced 
AMPK pathway. Furthermore, E4BP4 might reduce the 
AMPK-β1 stability in the liver to inhibit the AMPK pathway 
in response to chemical or diet-induced ER stress possibly 
by upregulating AMPK-specific E3 ligases. Taken together, 
our data reveal a novel molecular link between E4BP4 and 
ER stress-induced hepatic lipid accumulation during the 
pathogenesis of NAFLD and indicate that the suppression of 
hepatic E4BP4 activation might be a potential therapeutic av-
enue for treating NAFLD.
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